Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$19.25M+6059.36%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ameet Mallik
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 191
- Beta
- 1.85
- Country
- CH
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -8.28
Financials
Revenue
$19.25M+6059.4%Net Income
$-16.57MEBITDA
$-45.95MFree Cash Flow
$-11.81MEPS (diluted)
$-0.11Shares Outstanding (diluted)
155.02M+188.0%Operating Expenses
$39.64MCash & Debt
$219.11MReturn of Capital
$0.00Revenue by Segment (annual)
$81.36MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $81.36M | $-142.62M | $-1.12 |
| 2024 | $70.84M | $-157.85M | $-1.62 |
| 2023 | $69.56M | $-240.05M | $-2.94 |
| 2022 | $209.91M | $-157.13M | $-1.99 |
| 2021 | $33.92M | $-230.03M | $-3.00 |
| 2020 | $0.00 | $-246.29M | $-3.77 |
| 2019 | $2.34M | $-116.48M | $-1.74 |
| 2018 | $1.14M | $-123.10M | $-2.29 |
| 2017 | $1.80M | $-89.86M | $-1.53 |
Valuation
ADCThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (2)
- Newsseekingalpha.com·53d ago·Positive
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·53d ago·Negative
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.5 per share a year ago.
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $-0.21 per share
Typical surprise +23.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.11 vs $-0.22beat
- Mon, May 4$-0.21 vs $-0.19miss
- Tue, Mar 10$-0.04 vs $-0.32beat
- Mon, Nov 10$-0.30 vs $-0.40beat
- Tue, Aug 12$-0.50 vs $-0.36miss
- Wed, May 14$-0.36 vs $-0.38beat
Estimates and results for ADCT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ADCT officers and directors.
- Bought
- $5.7m
- Sold
- $19.9m
17 trades
15 trades
- Redmile Group, Llcsold
- Redmile Group, Llcsold
- Redmile Group, Llcsold
- Redmile Group, Llcsold
- Redmile Group, Llcsold
- Redmile Group, Llcsold
- Redmile Group, Llcbought
- Redmile Group, Llcbought
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ADCT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.